Loading...

EVOFEM BIOSCIENCES INC Capital Structure Changes 8-K Filing

VFM

EVOFEM BIOSCIENCES INC

()

2025 8-K

Distributorship Agreement

Securities Agreement Update

Agreement Termination

2025 Financial Results

Corporate Presentation Update

Annual Meeting Results

Financial Results Report

Merger Termination

Securities Purchase Amendment

Financial Results Report

Equity Offerings

Licensing Agreement

Financial Statements

Securities Agreement

License Agreement

Financial Results

External Links:

On June 26, 2025, Evofem Biosciences, Inc. completed a sale of senior subordinated convertible notes amounting to approximately $1.4 million and issued warrants for 92.4 million shares, generating net proceeds of about $925,000 for the company.

AI Assistant

EVOFEM BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.